The effects of GH and hormone replacement therapy on serum concentrations of mannan-binding lectin, surfactant protein D and vitamin D binding protein in Turner syndrome

European Journal of Endocrinology

Volumn 150, Issue 3, 2004, Pages 355-362

  Gravholt, Claus Højbjerg ^a   Leth Larsen, Rikke ^b   Lauridsen, Anna Lis ^a   Thiel, Steffen ^c   Hansen, Troels Krarup ^a   Holmskov, Uffe ^b   Naeraa, Rune Weis ^d   Christiansen, Jens Sandahl ^a  

^a AARHUS UNIVERSITY HOSPITAL   (Denmark)

^b UNIVERSITY OF SOUTHERN DENMARK   (Denmark)

^c AARHUS UNIVERSITY   (Denmark)

^d Randers Centralsygehus ^*  (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

BIOCHEMICAL MARKER; ESTRADIOL; ESTRADIOL PLUS NORETHISTERONE ACETATE; ESTROGEN; HUMAN GROWTH HORMONE; LEVONORGESTREL; MANNAN BINDING LECTIN; MEDROXYPROGESTERONE; NORETHISTERONE; NORETISTERONE; PLACEBO; PLASMA PROTEIN; SURFACTANT PROTEIN D; TRISEQUENS; VITAMIN D BINDING PROTEIN;

ADOLESCENT; ADULT; ARTICLE; CELLULAR IMMUNITY; CLINICAL OBSERVATION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; ESTROGEN THERAPY; FEMALE; HORMONE SUBSTITUTION; HUMAN; IMMUNE SYSTEM; IRRITANT DERMATITIS; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; SCHOOL CHILD; STATISTICAL SIGNIFICANCE; TURNER SYNDROME;

ADOLESCENT; ADULT; AGED; C-REACTIVE PROTEIN; CHILD; CROSS-OVER STUDIES; DOUBLE-BLIND METHOD; ESTRADIOL; ESTROGEN REPLACEMENT THERAPY; FEMALE; HAPTOGLOBINS; HUMAN GROWTH HORMONE; HUMANS; MANNOSE-BINDING LECTIN; MIDDLE AGED; NORETHINDRONE; PULMONARY SURFACTANT-ASSOCIATED PROTEIN D; TRANSFERRIN; TURNER SYNDROME; VITAMIN D-BINDING PROTEIN;

EID: 1842526922     PISSN: 08044643     EISSN: None     Source Type: Journal    
DOI: 10.1530/eje.0.1500355     Document Type: Article

References (44)

1. Anderson H, Filipsson R, Fluur E, Koch B, Lindsten J & Wedenberg E. Hearing impairment in Turner's syndrome. Acta Otolaryngologic 1969 (Suppl 247) 1-26.
2. Lippe B. Turner syndrome. Endocrinology and Metabolism Clinics of North America 1991 20 121-152.
3. Stenberg AE, Nylen O, Windh M & Hultcrantz M. Otological problems in children with Turner's syndrome. Hearing Research 1998 124 85-90.
4. Swerdlow AJ, Hermon C, Jacobs PA, Alberman E, Beral V, Daker M, Fordyce A & Youings S. Mortality and cancer incidence in persons with numerical sex chromosome abnormalities: A cohort study. Annals of Human Genetics 2001 65 177-188.
5. Gravholt CH. Aspects of the treatment of Turner syndrome. Expert Opinion on Pharmacotherapy 2001 2 1633-1647.
6. Hansen TK, Thiel S, Dall R, Rosenfalck AM, Trainer P, Flyvbjerg A, Jorgensen JO & Christiansen JS. GH strongly affects serum concentrations of mannan-binding lectin: Evidence for a new IGF-I independent immunomodulatory effect of GH. Journal of Clinical Endocrinology and Metabolism 2001 86 5383-5388.
7. Matsushita M & Fujita T. Activation of the classical complement pathway by mannose binding protein in association with a novel Cls-like serine protease. Journal of Experimental Medicine 1992 176 1497-1502.
8. Thiel S, Vorup-Jensen T, Stover CM, Schwaeble W, Laursen SB, Poulsen K, Willis AC, Eggleton P, Hansen S, Holmskov U, Reid KB & Jensenius JC. A second serine protease associated with mannan-binding lectin that activates complement. Nature 1997 386 506-510.
9. Turner MW. Mannose-binding lectin: The pluripotent molecule of the innate immune system. Immunology Today 1996 17 532-540.
10. Neth O, Jack DL, Dodds AW, Holzel H, Klein NJ & Turner MW. Mannose-binding lectin binds to a range of clinically relevant microorganisms and promotes complement deposition. Infection and Immunity 2000 68 688-693.
11. Hibberd ML, Sumiya M, Summerfield JA, Booy R & Levin M. Association of variants of the gene for mannose-binding lectin with susceptibility to meningococcal disease. Meningococcal Research Group. Lancet 1999 353 1049-1053.
12. Garred P, Madsen HO, Balstev U, Hofmann B, Pedersen C, Gerstoft J & Svejgaard A. Susceptibility to HIV infection and progression of AIDS in relation to variant alleles of mannose-binding lectin. Lancet 1997 349 236-240.
13. Super M, Thiel S, Lu J, Levinsky RJ & Turner MW. Association of low levels of mannan binding protein with a common defect of opsonisation. Lancet 1989 2 1236-1239.
14. Collard CD, Lekowski R, Jordan JE, Agah A & Stahl GL. Complement activation following oxidative stress. Molecular Immunology 1999 36 941-948.
15. Collard CD, Vakeva A, Morrissey MA, Agah A, Rollins SA, Reenstra WR, Buras JA, Meri S & Stahl GL. Complement activation after oxidative stress: Role of the lectin complement pathway. American Journal of Pathology 2000 156 1549-1556.
16. Jordan JE, Montalto MC & Stahl GL. Inhibition of mannose-binding lectin reduces postischemic myocardial reperfusion injury. Circulation 2001 104 1413-1418.
17. McCormack FX & Whitsett JA. The pulmonary collectins, SP-A and SP-D, orchestrate innate immunity in the lung. Journal of Clinical Investigation 2002 109 707-712.
18. Gravholt CH, Naeraa RW, Brixen K, Kastrup KW, Mosekilde L, Jørgensen JO & Christiansen JS. Short term growth hormone treatment in girls with Turner syndrome decreases fat mass and insulin sensitivity. A randomized double-blind, placebo-controlled cross-over study. Pediatrics 2002 110 889-896.
19. Gravholt CH, Lauridsen AL, Brixen K, Mosekilde L, Heickendorff L & Christiansen JS. Marked dysproportionality in bone size and mineral, and distinct abnormalities in bone markers and calcitropic hormones in adult Turner syndrome. A cross-sectional study. Journal of Clinical Endocrinology and Metabolism 2002 87 2798-2808.
20. Gravholt CH, Naeraa RW, Fisker S & Christiansen JS. Body composition and physical fitness are major determinants of the growth hormone-IGF axis aberrations in adult Turner syndrome, with important modulations by treatment with 17-beta estradiol. Journal of Clinical Endocrinology and Metabolism 1997 82 2570-2577.
21. Gravholt CH, Naeraa RW, Nyholm B, Gerdes U, Christiansen E, Schmitz O & Christiansen JS. Glucose metabolism, lipid metabolism, and cardiovascular risk factors in adult Turner syndrome: The impact of sex hormone replacement. Diabetes Care 1998 21 1062-1070.
22. Leth-Larsen R, Nordenbaek C, Tornoe I, Moeller V, Schlosser A, Koch C, Teisner B, Junker P & Holmskov U. Surfactant protein D (SP-D) serum levels in patients with community-acquired pneumonia small star, filled. Clincal Immunology 2003 108 29-37.
23. Lauridsen AL, Vestergaard P & Nexo E. Mean serum concentration of vitamin D-binding protein (Gc globulin) is related to the Gc phenotype in women. Clinical Chemistry 2001 47 753-756.
24. Valdimarsson H, Stefansson M, Vikingsdottir T, Arason GJ, Koch C, Thiel S & Jensenius JC. Reconstitution of opsonizing activity by infusion of mannan-binding lectin (MBL) to MBL-deficient humans. Scandinavian Journal of Immunology 1998 48 116-123.
25. Steffensen R, Thiel S, Varming K, Jersild C & Jensenius JC. Detection of structural gene mutations and promoter polymorphisms in the mannan-binding lectin (MBL) gene by polymerase chain reaction with sequence-specific primers. Journal of Immunology Methods 2000 241 33-42.
26. Jensen K, Petersen PH, Nielsen EL, Dahl G & Nielsen J. Serum immunoglobulin M, G, and A concentration levels in Turner's syndrome compared with normal women and men. Human Genetics 1976 31 329-334.
27. Lorini R, Ugazio AG, Cammareri V, Larizza D, Castellazzi AM, Brugo MA & Severi F. Immunoglobulin levels, T-cell markers, mitogen responsiveness and thymic hormone activity in Turner's syndrome. Thymus 1983 5 61-66.
28. Cacciari E, Masi M, Fantini MP, Licastro F, Cicognani A, Pirazzoli P, Villa MP, Specchia F, Forabosco A, Franceschi C & Martoni L. Serum immunoglobulins and lymphocyte subpopulations derangement in Turner's syndrome. Journal of Immunogenetics 1981 8 337-344.
29. al Attas RA, Rahi AH & Ahmed E. Common variable immunodeficiency with CD4 + T lymphocytopenia and overproduction of soluble IL-2 receptor associated with Turner's syndrome and dorsal kyphoscoliosis. Journal of Clinical Pathology 1997 50 876-879.
30. Robson SC & Potter PC. Common variable immunodeficiency in association with Turner's syndrome. Journal of Clinical and Laboratory Immunology 1990 32 143-146.
31. Hochberg Z, Aviram M, Rubin D & Pollack S. Decreased sensitivity to insulin-like growth factor I in Turner's syndrome: A study of monocytes and T lymphocytes. European Journal of Clinical Investigation 1997 27 543-547.
32. Kurabayashi T, Yasuda M, Fujimaki T, Yamamoto Y, Oda K & Tanaka K. Effect of hormone replacement therapy on spinal bone mineral density and T lymphocyte subsets in premature ovarian failure and Turner's syndrome. International Journal of Gynaecology and Obstetrics 1993 42 25-31.
33. Gupta S, Chiplunkar S, Gupta A & Gollapudi S. Increased spontaneous tumor necrosis factor receptor- and CD95 (Fas)-mediated apoptosis in cord blood T-cell subsets from Turner's syndrome. Genes and Immunity 2003 4 239-243.
34. Paananen R, Sormunen R, Glumoff V, van Eijk M & Hallman M. Surfactant proteins A and D in Eustachian tube epithelium. American Journal of Physiology. Lung Cellular and Molecular Physiology 2001 281 L660-L667.
35. Quigley CA, Crowe BJ, Anglin DG & Chipman JJ. Growth hormone and low dose estrogen in Turner syndrome: Results of a United States multi-center trial to near-final height. Journal of Clinical Endocrinology and Metabolism 2002 87 2033-2041.
36. Takala J, Ruokonen E, Webster NR, Nielsen MS, Zandstra DF, Vundelinckx G & Hinds CJ. Increased mortality associated with growth hormone treatment in critically ill adults. New England Journal of Medicine 1999 341 785-792.
37. Hansen TK, Thiel S, Wouters PJ, Christiansen JS & Van den BG. Intensive insulin therapy exerts anti inflammatory effects in critically ill patients and counteracts the adverse effect of low mannose-binding lectin levels. Journal of Clinical Endocrinology and Metabolism 2003 88 1082-1088.
38. Van den Berge G, Wouters P, Weekers F, Verwaest C, Bruyninckx F, Schetz M, Vlasselaers D, Ferdinande P, Lauwers P & Bouillon R. Intensive insulin therapy in the critically ill patients. New England Journal of Medicine 2001 345 1359-1367.
39. Haddad JG. Plasma vitamin D-binding protein (Gc-globulin): multiple tasks. Journal of Steroid Biochemistry and Molecular Biology 1995 53 579-582.
40. Norman AW, Bishop JE, Collins ED, Seo EG, Satchell DP, Dormanen MC, Zanello SB, Farach-Carson MC, Bouillon R & Okamura WH. Differing shapes of 1-alpha,25-dihydroxyvitamin D3 function as ligands for the D-binding protein, nuclear receptor and membrane receptor: A status report. Journal of Steroid Biochemistry and Molecular Biology 1996 56 13-22.
41. Berger D & Beger HG. Evidence for endotoxin binding capacity of human Gc-globulin and transferrin. Clinica Chimica Acta 1987 163 289-299.
42. Yamamoto N & Kumashiro R. Conversion of vitamin D3 binding protein (group-specific component) to a macrophage-activating factor by the stepwise action of betagalactosidase of B cells and sialidase of T cells. Journal of Immunology 1993 151 2794-2802.
43. van Hoof HJ, de Sevaux RG, Van Baelen H, Swinkels LM, Klipping C, Ross HA & Sweep CG. Relationship between free and total 1,25-dihydroxyvitamin D in conditions of modified binding. European Journal of Endocrinology 2001 144 391-396.
44. Vihervuori E, Sipila I & Siimes MA. Increases in hemoglobin concentration and iron needs in response to growth hormone treatment. Journal of Pediatrics 1994 125 242-245.